Renaissance Technologies LLC Purchases Shares of 24,670 Reata Pharmaceuticals, Inc. (RETA)
Renaissance Technologies LLC purchased a new stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 24,670 shares of the company’s stock, valued at approximately $559,000. Renaissance Technologies LLC owned approximately 0.11% of Reata Pharmaceuticals as of its most recent filing with the SEC.
Several other hedge funds also recently bought and sold shares of RETA. Teachers Advisors LLC boosted its stake in Reata Pharmaceuticals by 12.8% in the fourth quarter. Teachers Advisors LLC now owns 10,116 shares of the company’s stock valued at $221,000 after buying an additional 1,148 shares in the last quarter. Atlantic Trust Group LLC acquired a new stake in Reata Pharmaceuticals during the first quarter worth about $285,000. Fifth Third Bancorp acquired a new stake in Reata Pharmaceuticals during the first quarter worth about $395,000. Victory Capital Management Inc. acquired a new stake in Reata Pharmaceuticals during the first quarter worth about $483,000. Finally, Bank of New York Mellon Corp boosted its stake in Reata Pharmaceuticals by 18.1% in the first quarter. Bank of New York Mellon Corp now owns 22,213 shares of the company’s stock worth $503,000 after buying an additional 3,407 shares during the period. Institutional investors and hedge funds own 21.85% of the company’s stock.
Reata Pharmaceuticals, Inc. (NASDAQ RETA) traded up 2.97% during mid-day trading on Thursday, reaching $29.79. 54,973 shares of the company’s stock were exchanged. The company’s market cap is $777.61 million. The stock has a 50-day moving average price of $29.92 and a 200 day moving average price of $26.33. Reata Pharmaceuticals, Inc. has a 52-week low of $18.08 and a 52-week high of $41.60.
RETA has been the subject of a number of analyst reports. Citigroup Inc. reiterated a “buy” rating and issued a $87.00 target price (up from $39.00) on shares of Reata Pharmaceuticals in a research note on Tuesday, July 25th. Stifel Nicolaus reiterated a “buy” rating and issued a $50.00 target price (up from $38.00) on shares of Reata Pharmaceuticals in a research note on Tuesday, July 25th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $53.00 target price (up from $48.00) on shares of Reata Pharmaceuticals in a research note on Monday, June 5th. ValuEngine upgraded shares of Reata Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, May 27th. Finally, Zacks Investment Research cut shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $52.86.
In related news, Director James Edward Bass bought 8,064 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The shares were bought at an average price of $31.00 per share, with a total value of $249,984.00. Following the completion of the transaction, the director now directly owns 67,411 shares in the company, valued at $2,089,741. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder A/S Novo sold 61,000 shares of Reata Pharmaceuticals stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $25.11, for a total value of $1,531,710.00. Following the transaction, the insider now directly owns 642,405 shares in the company, valued at approximately $16,130,789.55. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 471,886 shares of company stock worth $12,541,056. 62.40% of the stock is owned by insiders.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Want to see what other hedge funds are holding RETA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Reata Pharmaceuticals, Inc. (NASDAQ:RETA).
Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.